#	Pagina
attuale pagina	/open-h2020/projects/225004/index.html
-1	/open-h2020/projects/196143/index.html
-2	/open-h2020/per-topic/deadliest/list/index.html
-3	/open-h2020/projects/213649/index.html
-4	/open-h2020/per-topic/iupac/list/index.html
-5	/open-h2020/per-topic/stores/list/index.html
-6	/open-consip/fornitori/2017/profilo-01034240521/index.html
-7	/open-h2020/projects/210304/results.html
-8	/open-h2020/projects/210304/deliverables.html
-9	/open-h2020/per-topic/outcompetes/list/index.html
-10	/open-h2020/projects/208376/results.html

Opendata, web and dolomites

StopAddict SIGNED

The game changer drug to cure alcohol use disorders

Total Cost €

EC-Contrib. €

Partnership

Views

StopAddict project word cloud

Explore the words cloud of the StopAddict project. It provides you a very rough idea of what is the project "StopAddict" about.

worldwide generating communities patients pharma 132 burden disability 2025 cumulative updated characterised uncontrolled therapeutics addiction deals newly dead treatments successful 70 ip million lives efficacy 2018 commercialisation damaging neuropsychopharmacology 10 stopaddict direct kinnov context mise 2027 regulatory granted clinical achievement patient mechanism disease suffer life trial treatment decreasing agency recovery implicated adjusted companies 283 french social fto accepted consumption actions leader aud smei2 therapies 117m licensing award 110 man indirect action leads create jobs persons discovered save drug society revolutionary alcoholism triple huge class expenses first people 2009 poor alcohol situation seeking kt college unsuccessful continuous disorders revenues families billion 400 intensive

Project "StopAddict" data sheet

The following table provides information about the project.

Coordinator	KINNOV THERAPEUTICS Organization address address: 3 ALLEE DU TITANE city: Orleans postcode: 45100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙432˙400 €
EC max contribution	2˙402˙680 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-10-01 to 2021-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KINNOV THERAPEUTICS KINNOV THERAPEUTICS Organization address address: 3 ALLEE DU TITANE city: Orleans postcode: 45100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Orleans)	coordinator	2˙402˙680.00

Map

Project objective

Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPADDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPADDICT" are provided by the European Opendata Portal: CORDIS opendata.